Skip to main content
. 2022 Jun 20;127(6):1142–1152. doi: 10.1038/s41416-022-01886-4

Fig. 3. M-CSF promotes the acquisition of Vemurafenib-resistance in BRAFV600E melanoma cells.

Fig. 3

a Levels of M-CSF in conditioned media of Vem-S and Vem-R cell lines determined by ELISA assay. b Viability and wound-healing assay of sensitive melanoma cells treated with Vemurafenib (1 μM, 48 h) and/or rhM-CSF (200 ng/mL). c Schematic representation of the in vitro assays. d MTT assay or e wound-healing assay of sensitive M3 and SK-Mel-28 cells after exposure to 48 h of their corresponding resistant CM treated with Vemurafenib (1 μM) and/or M-CSF mAb (20 ng/mL). f Wound-healing assay of Sk-Mel-28 cells cultivated with 10% of mice plasma from SCID mice with Sk-Mel-28R xenografts and treated with Vemurafenib (1 μM, 48 h) and/or M-CSF mAb (20 ng/mL). Graphs show mean + SEM. n = 3 independent experiments. Statistical analysis was performed using the ANOVA test, followed by Bonferroni’s multiple comparisons test (*p < 0.05; **p < 0.01; ***p < 0.001; ns, non-significant).